Control Bionics launched a Share Purchase Plan to raise up to AUD $500,000 at 7.5 cents per share, following an AUD $9.5M placement to professional investors announced a week earlier. The two-pronged raise will fund the company's pipeline of non-invasive initiatives and bolster working capital. Control Bionics makes EMG-based assistive communication devices, including the NeuroNode, and has recently been building out US distribution and reimbursement pathways for the platform.